Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000 Growth Index
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.85 USD | +9.76% | +5.27% | +2.48% |
04:37pm | UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating | MT |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.48% | 268M | |
+2.66% | 42.75B | |
+47.70% | 41.61B | |
+12.23% | 41.34B | |
-12.36% | 26.59B | |
+7.99% | 25.49B | |
-22.90% | 18.12B | |
+31.39% | 12.24B | |
-1.40% | 11.76B | |
+8.66% | 11B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc.(NasdaqGS: GLUE) dropped from Russell 3000 Growth Index